Top News "ICH Athens Meeting" to Be Held in a Hybrid Format for the First Time
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) plenary meeting for the first half of 2022 was held in Athens, Greece, from May 21 to 25, 2022.The meeting was conducted in a hybrid format—combining in-person and virtual sessions—for the first time in ICH history. Although the scale of the in-person component was smaller than in the past, many participants from around the world, including Japan, the United States, Europe, and Asia, gathered in Athens.
Group Photo
During this meeting, sessions were held including the Management Committee—which is responsible for preparing proposals for the Assembly and managing ICH operations—and the Assembly, in which all members participated. Additionally, discussions by expert working groups were conducted in parallel during the same period to advance the development of ICH guidelines.While ICH meetings had been held exclusively online for the past two and a half years, this event demonstrated how in-person meetings foster more in-depth discussions, clearly highlighting their importance.
The breakdown of participating organizations at the Athens meeting included six industry and government organizations from Japan, the U.S., and the EU (founding members); two standing members (Health Canada and Swissmedic); 12 member organizations; two Standing Observers; and 21 observers.Twelve representatives from the JPMA traveled to Athens.Since participants came from all over the world—including Japan, the U.S., Europe, and Asia—a core time slot was set each day to accommodate online participation from around the globe, and discussions on key issues were concentrated during that time. This core time slot was generally set from 2:00 PM to 4:00 PM Greek time. This corresponds to 8:00 PM to 10:00 PM in Japan and 7:00 AM to 9:00 AM on the U.S. East Coast.While this schedule worked well because this meeting was held in Europe, it would be impractical if the meeting were held in other regions. To ensure more efficient meeting operations, the Incheon meeting (South Korea) in the fall of 2022 will be held primarily in-person rather than in a hybrid format.
Notable items from the Athens meeting are listed below.
1. Approval of ICH Members and Observers
The UK Medicines and Healthcare products Regulatory Agency (MHRA) was approved as a new ICH member.The MHRA previously operated as a founding regulatory member of the European Commission (EC), but lost that status following the United Kingdom’s withdrawal from the European Union (EU). Since then, it has participated as an independent observer organization, and its promotion to full membership was approved following an expedited process.In addition, the Algerian National Agency for Medicines (ANPP) has been approved as a new observer.
As a result, the number of ICH members has increased by one from 19 to 20, while the number of observers has increased by one and decreased by one, bringing the total to 35. ICH now comprises a total of 55 organizations (see reference materials at the end).
2. Trends in ICH Topics
At the Athens meeting, discussions on technical topics were also held in a hybrid format (in-person/web conference). Although the number of working groups was smaller than usual, working groups for all seven topics listed below made active use of this period to hold meetings and achieve progress.In addition, the Management Committee and the Assembly addressed progress management for all existing topics, made decisions on Step transitions, and discussed new topics.
Expert and Implementation Working Groups
The following seven topics were discussed at the Athens meeting:
- •E6 (R3): Revision of "Good Clinical Practice"
- •M4Q(R2): Revision of "the Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality"
- •M10: Bioanalytical Method Validation and Study Sample Analysis
- •Q5A(R2): Revision of "Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin"
- •Q9(R1): Rivision of "Quality Risk Management"
- •Q13: Continuous Manufacturing of Drug Substances and Drug Products
- •S1B (R1): Addendum to the Guideline on Testing for Carcinogenicity of Pharmaceuticals
Reached Step 4
Reach of Step 4 has been reported for the following topics. These will now enter the implementation process at each regulatory authority.
- •M10: Bioanalytical Method Validation and Study Sample Analysis
- •M8: Q&A Regarding “Electronic Specifications for eCTD (Electronic Common Technical Document) v4.0” v1.7 and eCTD v4.0 Implementation Guide v1.5
Reached Step 2
M12: It has been reported that Step 2 has been reached for "Drug Interactions Studies." Public comment periods will be held in each country and region going forward.
Approval of New Topics
In preparation for launching a new working group to develop guidelines, “Inclusion of Pregnant and Lactating Women in Clinical Trials” was adopted.
3. Next ICH Meeting
The meeting is scheduled to take place in Incheon, South Korea, from November 12 to 16, 2022. Based on the experience gained at the recent Athens meeting, the event is planned to be held in person, in principle.
Furthermore, ICH actively discloses information regarding its activities, including the outcomes of ICH meetings, to foster a deeper understanding not only among stakeholders but also among the general public. The outcomes of this ICH Athens meeting, as well as concept papers and work plans for each topic, are available on the ICH website ( https://www.ich.org/ ).
[Reference Material: List of ICH Members and Observers (as of June 2022)]
Table 1: Members (20 organizations)
Table 2: Observers (35 organizations)
( Mariko Kato, Director, International Regulatory Coordination Division)
